Clinical efficacy of Atezolizumab/Bevacizumab combined with TACE in treating BCLC stage C hepatocellular carcinoma.

Front Oncol · 2026 · PMC13043440 · PMID 41939459

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

For instance, the LEAP-012 study demonstrated that TACE combined with lenvatinib and pembrolizumab significantly improved progression-free survival compared with TACE alone in patients with unresectable, non-metastatic HCC, with a favorable trend in overall survival ( 2 ).

also in 993 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.